8/12/2023 0 Comments Kite pharma investor presentation![]() ![]() ![]() Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information, visit To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device. Cryoport is the preferred cryogenic logistics solutions partner to the world’s largest shipping companies controlling more than 85% of the world’s air shipments. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150☌ temperature for a 10 day dynamic shipment duration. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO’s, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. We are delighted that Cryoport’s validated cryogenic logistics solutions will support Kite in moving closer to eradicating this deadly disease.” About Cryoport, Inc.Ĭryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. Jerrell Shelton, Chief Executive Officer of Cryoport, stated, “We are honored to provide services and solutions to Kite in their efforts to advance a novel immunotherapy treatment that addresses the significant, unmet needs of patients with NHL. ![]() We are grateful for their professionalism and their support in a role that is contributing greatly to our progress.” Kite is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous T cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors.ĭavid Chang, M.D., Ph.D., Kite’s Executive Vice President of Research and Development and Chief Medical Officer, commented, “Cryoport has provided valuable cryogenic logistics solutions for our lead clinical program. (OTCBB: CYRX) (“Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers and reproductive medicine, today announced that the Company’s best-in-class logistics solution is supporting Kite Pharma’s (“Kite”) clinical program for their lead product candidate, KTE-C19, a CAR-T cell therapy for non-Hodgkin’s lymphoma (“NHL”). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |